Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients
Abstract Background The Oncomine™ Dx Target Test based on next-generation sequencing has been approved for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients. Methods We assessed the tissue sample factors that affect the success rate of Oncomine™ Dx Target Test comp...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of clinical oncology 2021-07, Vol.51 (7), p.1114-1122 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1122 |
|---|---|
| container_issue | 7 |
| container_start_page | 1114 |
| container_title | Japanese journal of clinical oncology |
| container_volume | 51 |
| creator | Takeyasu, Yuki Yoshida, Tatsuya Motoi, Noriko Teishikata, Takashi Tanaka, Midori Matsumoto, Yuji Shinno, Yuki Okuma, Yusuke Goto, Yasushi Horinouchi, Hidehito Kakishima, Hiroki Tsuchida, Takaaki Yamamoto, Noboru Ohe, Yuichiro Yatabe, Yasushi |
| description | Abstract
Background
The Oncomine™ Dx Target Test based on next-generation sequencing has been approved for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients.
Methods
We assessed the tissue sample factors that affect the success rate of Oncomine™ Dx Target Test companion diagnostics and the feasibility of using biopsy specimens for Oncomine™ Dx Target Test companion diagnostics in advanced non-small-cell lung cancer patients.
Results
Ninety-nine biopsy samples were subjected to genetic testing using the Oncomine™ Dx Target Test companion diagnostics to detect v-raf murine sarcoma viral oncogene homologue B1 mutations (Cohort 1), and 136 biopsy samples were examined using Oncomine™ Dx Target Test companion diagnostics for the detection of multiple oncogenic mutations (Cohort 2) between July 2018 and April 2020. We retrospectively collected clinical and pathological data, including tissue size and tumour cell content. The success rate was 77% (76/99) in Cohort 1 and 93% (127/136) in Cohort 2. In Cohort 1, the success rate was significantly associated with the tumour cell content: the success rate was 63% for samples with a tumour cell content of |
| doi_str_mv | 10.1093/jjco/hyab059 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2516221072</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jjco/hyab059</oup_id><sourcerecordid>2516221072</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-c396728de658f26a1faeb9831abe29e0cf01d5d48e495e33008464a0d97c5f7f3</originalsourceid><addsrcrecordid>eNp9kU1LxDAQhoMoft88S24qWDdp-nkUv0HwsoK3kqaT3SxtsiapuHf_h-BP85eYuqt48jQD88zDDC9CB5ScUVKy0WwmzGi64DVJyzW0TZMsjVgW0_U__RbacW5GCEmLJN9EW4wVBaUs30bv18CdqlWr_AIbiTW8-mgCGiz3ymjs4LkHLZSe4OMHLUynNHy-feDLJzzmdgIej8H5EyyNxX4K2AkLoAc8yExYCC4lcNf7b5_DSmPevHAtoMHa6Mh1vG0jAW2L2z6siWFk8TzgoL3bQxuStw72V3UXPV5fjS9uo_uHm7uL8_tIJJT5SLAyy-OigSwtZJxxKjnUZcEoryEugQhJaJM2SQFJmQJjhBRJlnDSlLlIZS7ZLjpeeufWhI-drzrlhqu4BtO7Kk5pFseU5HFAT5eosMY5C7KaW9Vxu6goqYZIqiGSahVJwA9X5r7uoPmFfzIIwNESMP38f9UXg3SaOA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2516221072</pqid></control><display><type>article</type><title>Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Takeyasu, Yuki ; Yoshida, Tatsuya ; Motoi, Noriko ; Teishikata, Takashi ; Tanaka, Midori ; Matsumoto, Yuji ; Shinno, Yuki ; Okuma, Yusuke ; Goto, Yasushi ; Horinouchi, Hidehito ; Kakishima, Hiroki ; Tsuchida, Takaaki ; Yamamoto, Noboru ; Ohe, Yuichiro ; Yatabe, Yasushi</creator><creatorcontrib>Takeyasu, Yuki ; Yoshida, Tatsuya ; Motoi, Noriko ; Teishikata, Takashi ; Tanaka, Midori ; Matsumoto, Yuji ; Shinno, Yuki ; Okuma, Yusuke ; Goto, Yasushi ; Horinouchi, Hidehito ; Kakishima, Hiroki ; Tsuchida, Takaaki ; Yamamoto, Noboru ; Ohe, Yuichiro ; Yatabe, Yasushi</creatorcontrib><description>Abstract
Background
The Oncomine™ Dx Target Test based on next-generation sequencing has been approved for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients.
Methods
We assessed the tissue sample factors that affect the success rate of Oncomine™ Dx Target Test companion diagnostics and the feasibility of using biopsy specimens for Oncomine™ Dx Target Test companion diagnostics in advanced non-small-cell lung cancer patients.
Results
Ninety-nine biopsy samples were subjected to genetic testing using the Oncomine™ Dx Target Test companion diagnostics to detect v-raf murine sarcoma viral oncogene homologue B1 mutations (Cohort 1), and 136 biopsy samples were examined using Oncomine™ Dx Target Test companion diagnostics for the detection of multiple oncogenic mutations (Cohort 2) between July 2018 and April 2020. We retrospectively collected clinical and pathological data, including tissue size and tumour cell content. The success rate was 77% (76/99) in Cohort 1 and 93% (127/136) in Cohort 2. In Cohort 1, the success rate was significantly associated with the tumour cell content: the success rate was 63% for samples with a tumour cell content of <20%, whereas it was 83% for samples with a tumour cell content of 20% or higher (P = 0.0446). The tissue size also affected the success rate: a success rate of 57% was obtained for tissue sizes <4 mm2, whereas a success rate of 95% was obtained for tissue sizes of 4 mm2 or larger (P < 0.0001). In Cohort 2, the success rate was 100% when tumour specimens with a tissue size of 4 mm2 or larger were used.
Conclusions
Tissue size and tumour cell content were significantly associated with the success rate of Oncomine™ Dx Target Test companion diagnostics.
We identified both tumour cell content (20% or more) and tissue sample size (4 mm2 or more) affected the success rate of Oncomine™ Dx Target Test in patients with advanced non-small-cell lung cancer.</description><identifier>ISSN: 1465-3621</identifier><identifier>EISSN: 1465-3621</identifier><identifier>DOI: 10.1093/jjco/hyab059</identifier><identifier>PMID: 33881137</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><ispartof>Japanese journal of clinical oncology, 2021-07, Vol.51 (7), p.1114-1122</ispartof><rights>The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-c396728de658f26a1faeb9831abe29e0cf01d5d48e495e33008464a0d97c5f7f3</citedby><cites>FETCH-LOGICAL-c413t-c396728de658f26a1faeb9831abe29e0cf01d5d48e495e33008464a0d97c5f7f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33881137$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Takeyasu, Yuki</creatorcontrib><creatorcontrib>Yoshida, Tatsuya</creatorcontrib><creatorcontrib>Motoi, Noriko</creatorcontrib><creatorcontrib>Teishikata, Takashi</creatorcontrib><creatorcontrib>Tanaka, Midori</creatorcontrib><creatorcontrib>Matsumoto, Yuji</creatorcontrib><creatorcontrib>Shinno, Yuki</creatorcontrib><creatorcontrib>Okuma, Yusuke</creatorcontrib><creatorcontrib>Goto, Yasushi</creatorcontrib><creatorcontrib>Horinouchi, Hidehito</creatorcontrib><creatorcontrib>Kakishima, Hiroki</creatorcontrib><creatorcontrib>Tsuchida, Takaaki</creatorcontrib><creatorcontrib>Yamamoto, Noboru</creatorcontrib><creatorcontrib>Ohe, Yuichiro</creatorcontrib><creatorcontrib>Yatabe, Yasushi</creatorcontrib><title>Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients</title><title>Japanese journal of clinical oncology</title><addtitle>Jpn J Clin Oncol</addtitle><description>Abstract
Background
The Oncomine™ Dx Target Test based on next-generation sequencing has been approved for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients.
Methods
We assessed the tissue sample factors that affect the success rate of Oncomine™ Dx Target Test companion diagnostics and the feasibility of using biopsy specimens for Oncomine™ Dx Target Test companion diagnostics in advanced non-small-cell lung cancer patients.
Results
Ninety-nine biopsy samples were subjected to genetic testing using the Oncomine™ Dx Target Test companion diagnostics to detect v-raf murine sarcoma viral oncogene homologue B1 mutations (Cohort 1), and 136 biopsy samples were examined using Oncomine™ Dx Target Test companion diagnostics for the detection of multiple oncogenic mutations (Cohort 2) between July 2018 and April 2020. We retrospectively collected clinical and pathological data, including tissue size and tumour cell content. The success rate was 77% (76/99) in Cohort 1 and 93% (127/136) in Cohort 2. In Cohort 1, the success rate was significantly associated with the tumour cell content: the success rate was 63% for samples with a tumour cell content of <20%, whereas it was 83% for samples with a tumour cell content of 20% or higher (P = 0.0446). The tissue size also affected the success rate: a success rate of 57% was obtained for tissue sizes <4 mm2, whereas a success rate of 95% was obtained for tissue sizes of 4 mm2 or larger (P < 0.0001). In Cohort 2, the success rate was 100% when tumour specimens with a tissue size of 4 mm2 or larger were used.
Conclusions
Tissue size and tumour cell content were significantly associated with the success rate of Oncomine™ Dx Target Test companion diagnostics.
We identified both tumour cell content (20% or more) and tissue sample size (4 mm2 or more) affected the success rate of Oncomine™ Dx Target Test in patients with advanced non-small-cell lung cancer.</description><issn>1465-3621</issn><issn>1465-3621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kU1LxDAQhoMoft88S24qWDdp-nkUv0HwsoK3kqaT3SxtsiapuHf_h-BP85eYuqt48jQD88zDDC9CB5ScUVKy0WwmzGi64DVJyzW0TZMsjVgW0_U__RbacW5GCEmLJN9EW4wVBaUs30bv18CdqlWr_AIbiTW8-mgCGiz3ymjs4LkHLZSe4OMHLUynNHy-feDLJzzmdgIej8H5EyyNxX4K2AkLoAc8yExYCC4lcNf7b5_DSmPevHAtoMHa6Mh1vG0jAW2L2z6siWFk8TzgoL3bQxuStw72V3UXPV5fjS9uo_uHm7uL8_tIJJT5SLAyy-OigSwtZJxxKjnUZcEoryEugQhJaJM2SQFJmQJjhBRJlnDSlLlIZS7ZLjpeeufWhI-drzrlhqu4BtO7Kk5pFseU5HFAT5eosMY5C7KaW9Vxu6goqYZIqiGSahVJwA9X5r7uoPmFfzIIwNESMP38f9UXg3SaOA</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Takeyasu, Yuki</creator><creator>Yoshida, Tatsuya</creator><creator>Motoi, Noriko</creator><creator>Teishikata, Takashi</creator><creator>Tanaka, Midori</creator><creator>Matsumoto, Yuji</creator><creator>Shinno, Yuki</creator><creator>Okuma, Yusuke</creator><creator>Goto, Yasushi</creator><creator>Horinouchi, Hidehito</creator><creator>Kakishima, Hiroki</creator><creator>Tsuchida, Takaaki</creator><creator>Yamamoto, Noboru</creator><creator>Ohe, Yuichiro</creator><creator>Yatabe, Yasushi</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210701</creationdate><title>Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients</title><author>Takeyasu, Yuki ; Yoshida, Tatsuya ; Motoi, Noriko ; Teishikata, Takashi ; Tanaka, Midori ; Matsumoto, Yuji ; Shinno, Yuki ; Okuma, Yusuke ; Goto, Yasushi ; Horinouchi, Hidehito ; Kakishima, Hiroki ; Tsuchida, Takaaki ; Yamamoto, Noboru ; Ohe, Yuichiro ; Yatabe, Yasushi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-c396728de658f26a1faeb9831abe29e0cf01d5d48e495e33008464a0d97c5f7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Takeyasu, Yuki</creatorcontrib><creatorcontrib>Yoshida, Tatsuya</creatorcontrib><creatorcontrib>Motoi, Noriko</creatorcontrib><creatorcontrib>Teishikata, Takashi</creatorcontrib><creatorcontrib>Tanaka, Midori</creatorcontrib><creatorcontrib>Matsumoto, Yuji</creatorcontrib><creatorcontrib>Shinno, Yuki</creatorcontrib><creatorcontrib>Okuma, Yusuke</creatorcontrib><creatorcontrib>Goto, Yasushi</creatorcontrib><creatorcontrib>Horinouchi, Hidehito</creatorcontrib><creatorcontrib>Kakishima, Hiroki</creatorcontrib><creatorcontrib>Tsuchida, Takaaki</creatorcontrib><creatorcontrib>Yamamoto, Noboru</creatorcontrib><creatorcontrib>Ohe, Yuichiro</creatorcontrib><creatorcontrib>Yatabe, Yasushi</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Takeyasu, Yuki</au><au>Yoshida, Tatsuya</au><au>Motoi, Noriko</au><au>Teishikata, Takashi</au><au>Tanaka, Midori</au><au>Matsumoto, Yuji</au><au>Shinno, Yuki</au><au>Okuma, Yusuke</au><au>Goto, Yasushi</au><au>Horinouchi, Hidehito</au><au>Kakishima, Hiroki</au><au>Tsuchida, Takaaki</au><au>Yamamoto, Noboru</au><au>Ohe, Yuichiro</au><au>Yatabe, Yasushi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients</atitle><jtitle>Japanese journal of clinical oncology</jtitle><addtitle>Jpn J Clin Oncol</addtitle><date>2021-07-01</date><risdate>2021</risdate><volume>51</volume><issue>7</issue><spage>1114</spage><epage>1122</epage><pages>1114-1122</pages><issn>1465-3621</issn><eissn>1465-3621</eissn><abstract>Abstract
Background
The Oncomine™ Dx Target Test based on next-generation sequencing has been approved for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients.
Methods
We assessed the tissue sample factors that affect the success rate of Oncomine™ Dx Target Test companion diagnostics and the feasibility of using biopsy specimens for Oncomine™ Dx Target Test companion diagnostics in advanced non-small-cell lung cancer patients.
Results
Ninety-nine biopsy samples were subjected to genetic testing using the Oncomine™ Dx Target Test companion diagnostics to detect v-raf murine sarcoma viral oncogene homologue B1 mutations (Cohort 1), and 136 biopsy samples were examined using Oncomine™ Dx Target Test companion diagnostics for the detection of multiple oncogenic mutations (Cohort 2) between July 2018 and April 2020. We retrospectively collected clinical and pathological data, including tissue size and tumour cell content. The success rate was 77% (76/99) in Cohort 1 and 93% (127/136) in Cohort 2. In Cohort 1, the success rate was significantly associated with the tumour cell content: the success rate was 63% for samples with a tumour cell content of <20%, whereas it was 83% for samples with a tumour cell content of 20% or higher (P = 0.0446). The tissue size also affected the success rate: a success rate of 57% was obtained for tissue sizes <4 mm2, whereas a success rate of 95% was obtained for tissue sizes of 4 mm2 or larger (P < 0.0001). In Cohort 2, the success rate was 100% when tumour specimens with a tissue size of 4 mm2 or larger were used.
Conclusions
Tissue size and tumour cell content were significantly associated with the success rate of Oncomine™ Dx Target Test companion diagnostics.
We identified both tumour cell content (20% or more) and tissue sample size (4 mm2 or more) affected the success rate of Oncomine™ Dx Target Test in patients with advanced non-small-cell lung cancer.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>33881137</pmid><doi>10.1093/jjco/hyab059</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-3621 |
| ispartof | Japanese journal of clinical oncology, 2021-07, Vol.51 (7), p.1114-1122 |
| issn | 1465-3621 1465-3621 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2516221072 |
| source | Oxford University Press Journals All Titles (1996-Current); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T07%3A46%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20of%20next-generation%20sequencing%20(Oncomine%E2%84%A2%20DX%20Target%20Test)%20for%20the%20screening%20of%20oncogenic%20mutations%20in%20advanced%20non-small-cell%20lung%20cancer%20patients&rft.jtitle=Japanese%20journal%20of%20clinical%20oncology&rft.au=Takeyasu,%20Yuki&rft.date=2021-07-01&rft.volume=51&rft.issue=7&rft.spage=1114&rft.epage=1122&rft.pages=1114-1122&rft.issn=1465-3621&rft.eissn=1465-3621&rft_id=info:doi/10.1093/jjco/hyab059&rft_dat=%3Cproquest_cross%3E2516221072%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2516221072&rft_id=info:pmid/33881137&rft_oup_id=10.1093/jjco/hyab059&rfr_iscdi=true |